Seeing ophthalmologic problems in Parkinson disease

Results of a visual impairment questionnaire

Carlijn D.J.M. Borm, MD,* Femke Visser, MD,* Mario Werkmann, MD, Debbie de Graaf, MSc, Diana Putz, MD, Klaus Seppi, MD, Werner Poewe, MD, Annemarie M.M. Vlaar, MD, PhD, Carel Hoyng, MD, PhD, Bastiaan R. Bloem, MD, PhD, Thomas Theelen, MD, PhD, and Nienke M. de Vries, PhD


Abstract

Objective
To determine the prevalence and clinical effect of ophthalmologic symptoms in patients with Parkinson disease (PD), compared with controls, using a standardized questionnaire.

Methods
In this observational, cross-sectional, multicenter study, 848 patients with PD and 250 healthy controls completed the Visual Impairment in Parkinson’s Disease Questionnaire (VIPD-Q). The VIPD-Q addressed 4 domains according to structures: (1) ocular surface; (2) intraocular; (3) oculomotor; and (4) optic nerve. The questionnaire also assessed the effect of ophthalmologic symptoms on daily activities.

Results
One or more ophthalmologic symptoms were reported by 82% (95% confidence interval [CI], 80–85) of patients, compared with 48% (95% CI, 42–54) of controls (p < 0.001). Patients with PD experienced more ophthalmologic symptoms across all domains than controls (p < 0.001), as reflected by a higher VIPD-Q total score among patients (median 10 [interquartile range [IQR] 13]) than controls (median 2 [IQR 5]; p < 0.001). Ophthalmologic symptoms interfered with daily activities in 68% (95% CI, 65–71) of patients, compared with 35% (95% CI, 29–41) of controls (p < 0.001).

Conclusion
Patients with PD have a higher prevalence of ophthalmologic symptoms than controls. Moreover, these frequently interfere with daily activities. A screening questionnaire such as the VIPD-Q may help with identifying ophthalmologic symptoms in PD, thereby enabling more timely treatment.

*These authors contributed equally to this work.

Correspondence
Dr. Borm
carlijn.borm@radboudumc.nl

From Parkinson Centre Nijmegen (ParC), Department of Neurology, Donders Institute for Brain, Cognition and Behaviour (C.D.J.M.B., D.d.G., B.R.B., N.M.d.V.), and Department of Ophthalmology (C.H., T.T.), Radboud University Medical Centre, Nijmegen; Department of Neurology (F.V., A.M.M.V.), Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, the Netherlands; and Departments of Neurology (M.W., K.S., W.P.) and Ophthalmology (D.P.), Medical University Innsbruck, Austria.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Glossary

CI = confidence interval; IQR = interquartile range; LED = levodopa equivalent dose; OLVG = Onze Lieve Vrouwe Gasthuis; PD = Parkinson disease; VIPD-Q = Visual Impairment in Parkinson’s Disease Questionnaire.

Ophthalmologic symptoms are underreported by patients with Parkinson disease (PD) and often overlooked by their treating physicians. The most commonly reported ophthalmologic symptoms include double vision, blurry vision, watery eyes, and visual hallucinations. In PD, retinal dopamine depletion and decreased dopaminergic innervation of the visual cortex can lead to various visual problems, including impairments of oculomotor control, contrast sensitivity, color vision, and visuospatial construction. Also, patients with PD have an increased risk of seborrheic blepharitis and keratoconjunctivitis sicca (dry eyes). As almost 80% of visual impairments worldwide are treatable or preventable, timely ophthalmologic symptoms in PD.10 First studies in this PD compared with controls, and to explore the extent and frequency of ophthalmologic symptoms in a large sample of patients with 

Methods

Study design
This multicenter, cross-sectional study is part of a larger study on visual impairments in PD. The protocol has been published previously.13 We used a newly developed screening questionnaire—the Visual Impairment in Parkinson’s Disease Questionnaire (VIPD-Q)—to gain insight into the prevalence and clinical effect of ophthalmologic symptoms in patients with PD. The questionnaire was sent out by 3 study centers, 2 university hospitals (Radboudumc Nijmegen, the Netherlands; and the Medical University Innsbruck, Austria), and 1 general hospital (Onze Lieve Vrouwe Gasthuis [OLVG], Amsterdam, the Netherlands) between December 2016 and July 2018. Each center obtained local ethical approval. This study was performed in accordance with the Declaration of Helsinki. All respondents participated anonymously and voluntarily.

Samples
We used multiple methods to recruit patients. At Radboudumc, an open Web link was circulated by email to a panel of patients with PD interested in research (n = 350) and in the outpatient clinic. The questionnaire was sent by mail to all patients treated for PD in OLVG (n = 476). In Innsbruck, the questionnaire was completed during patient interviews at the outpatient clinic, where all scheduled patients with PD were invited to participate (n = 300). Controls were recruited from partners and acquaintances of patients with PD.

Standard protocol approvals, registrations, and patient consents
Dutch Trial Registration, NL7421; ethical approval information: NLS8535.091.16, Nijmegen, the Netherlands; and AN2016-0181, Innsbruck, Austria.

Measures
The VIPD-Q was developed by neurologists and ophthalmologists to detect a broad range of ophthalmologic disorders, and was based on extensive literature study, other questionnaires, and common and disabling ophthalmologic disorders, and was based on extensive literature study, other questionnaires, and common and disabling ophthalmologic disorders in patients with PD and healthy older people.1,3,9,11,14–25

The original questionnaire included 22 questions on ophthalmologic symptoms. This number of items was reduced to 17 after a revision round that aimed to improve readability and face validity. The questionnaire also includes a standard set of demographic questions. We categorized the VIPD-Q into 4 domains of ophthalmologic disorders, according to ocular structures: (1) ocular surface; (2) intraocular; (3) oculomotor; and (4) optic nerve. Each domain consists of 4 questions. There is 1 question on visual hallucinations. The questions of the VIPD-Q can be found in table 1 and the questionnaire is described in more detail in a former publication.13 Answers were given on a 4-point Likert scale ranging from “never have symptoms” to “daily symptoms,” without an option for a neutral answer.

Outcomes included the prevalence of ophthalmologic symptoms, with presence for each specific question being defined as a score of 2 or higher (i.e., “every week” or “every day”), except for the question on visual hallucinations, where a score of 1 or higher (≥ once/mo) was considered as having visual hallucinations. We calculated the total score of the VIPD-Q (only for complete questionnaires), the score per domain (when all questions relating to a domain were answered), and the scores for individual questions related to a specific ophthalmologic symptom (i.e., double vision,
hallucinations). The maximum total score is 51 (when all 17 questions are answered with “daily”), and the maximum score per domain is 12 points. The influence of ophthalmologic symptoms on daily activities (i.e., reading, driving a car, working on the computer, watching television, performing hobbies, walking, personal care) was scored with yes or no questions, whether or not the patient experienced problems in that specific activity because of ophthalmologic symptoms. Participants were also asked about the number of falls in the last 6 months. Quality of life was assessed based on the question “Do ophthalmologic symptoms influence your quality of life?” Answer possibilities were “no effect,” “moderate effect,” or “severe effect.”

Statistical analysis
We compared patients with PD with controls using $\chi^2$ tests for categorical values (sex, education, comorbidity, visited ophthalmologist, visual aid, vision changes during the day, difficulties with daily activities, effect on quality of life) and Mann-Whitney U test for nonparametric continuous variables (age, total VIPD-Q score, score per domain, levodopa equivalent dose [LED]).

To identify the influence of ophthalmologic symptoms on falling, a multiple regression analysis was conducted, with correction for potential confounders (age, sex, LED, and disease duration). A multivariate logistic regression analysis was performed to investigate the association between ophthalmologic symptoms as reflected by the total VIPD-Q score and disease duration, adjusted for sex, age, and LED. For internal consistency, $\omega$ total, Cronbach coefficient $\alpha$, and greater lower bound were calculated. A $p$ value < 0.05 was considered significant. Statistical analyses were conducted using SPSS 22.0 (SPSS Inc., IBM, Chicago, IL) and SAS (SAS Institute Inc, Cary, NC) statistical software.

Data availability
Requests for data from the VIP Study will be considered by B.R.B. in line with data protection laws. The general policy is that as long as the proposed use of the data is scientifically
Valid and if ethics approval permits, suitably anonymized data can be shared with other researchers.

Results
A total of 1,098 participants completed the questionnaire: 848 patients with PD and 250 age-matched controls (ratio of 3:1). Among patients with PD, 288 participants completed the questionnaire online, 308 by mail, and 252 by interview in the outpatient clinic. We could not calculate the exact response rate for the online completed questionnaires, since it was not possible to determine how many potential respondents visited our online platform, but the invitation to fill out the questionnaire was sent out to 350 patients (of whom 288 completed the questionnaire [82%]). The response rate was 65% (308/476) by mail and 84% (252/300) by interview. The mean time needed to complete the questionnaire measured online and during interview was 20 minutes.

Participant characteristics
Table 2 summarizes the baseline characteristics. The 2 groups were well-balanced for education and comorbidity. The median age of the participants was 70 years in both groups, with a slightly higher percentage of men among patients with PD (60%) than controls (52%) \(F_1 = 4.755, p = 0.029\). Patients with PD consulted the ophthalmologist and used visual aids more often than controls. Compared with controls, more patients with PD experienced visual changes during the day (38% vs 19%; \(F_1 = 29.695; p < 0.001\)) and more patients with PD stated that their visual aid was not working properly (28% vs 17%; \(F_1 = 11.277; p = 0.001\)). As expected, the use of a walking aid when walking outdoors was significantly higher among patients with PD (37%) than controls (7%) \(F_1 = 81.46; p < 0.001\).

Prevalence of ophthalmologic symptoms
Among patients with PD, one or more ophthalmologic symptoms were present in 82% (95% confidence interval [CI], 80–85), compared with 48% (95% CI, 42–54) of the controls \(F_1 = 118.53; p < 0.001\). Table 1 provides the percentages of ophthalmologic symptoms reported per question for both groups. Some ophthalmologic symptoms were found almost exclusively in PD (e.g., seeing colors less brightly, double vision, difficulty with depth perception, visual hallucinations), whereas others were also common in controls (e.g., watery eyes, light sensitivity, and glare at night). However, all ophthalmologic symptoms were significantly more prevalent in patients than in controls.

Patients with PD experienced more ophthalmologic symptoms simultaneously than controls, as reflected by the median total score on the VIPD-Q (PD: median score 10 [interquartile range (IQR) 5, range 0–48]; controls: median score 2 [IQR 5], range 0–30; Mann-Whitney \(U = 38,781; n_1 = n_2 = 997; p < 0.001\)), shown in figure 1. Total scores did not differ between men and women with PD \(F_1 = 0.238; p = 0.780\). Among controls, women had significantly higher scores than men \(F_1 = 7.223; p = 0.007\). Figure 2 shows the number of ophthalmologic symptoms per domain for both groups. Symptoms related to the ocular surface were most common among patients (PD: 63%; controls: 24%; \(\chi^2 \left[1, n = 1,081\right] = 120.73; p < 0.001\), followed by symptoms in the intraocular domain (PD: 54%; controls: 25%; \(p < 0.001\)), then ocular motor domain (PD: 44%; controls: 10%; \(p < 0.001\)) and optic nerve domain (PD: 44%; controls: 19%; \(p < 0.001\)). The prevalence of visual hallucinations was 22% among patients with PD compared with only 2% among controls \(p < 0.001\).

Patients with PD who participated through the open Web link had a slightly higher prevalence of ophthalmologic symptoms (87%) and a higher median total score on the VIPD-Q (score 13) than patients who participated by mail (81%; score 9) or by interview (79%; score 8).

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Participant characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PD (n = 848)</td>
</tr>
<tr>
<td>Men, n (%)</td>
<td>467 (60)</td>
</tr>
<tr>
<td>Age, y, median (IQR) [range]</td>
<td>70 (12.5) [33–93]</td>
</tr>
<tr>
<td>Disease duration, y, median (IQR) [range]</td>
<td>7 (7.0) [1–39]</td>
</tr>
<tr>
<td>Levodopa dose equivalent, mg, median (IQR) [range]</td>
<td>579 (757) [0–2,147]</td>
</tr>
<tr>
<td>Education, college degree, n (%)</td>
<td>272 (32)</td>
</tr>
<tr>
<td>Country of birth (within Europe), n (%)</td>
<td>803 (96)</td>
</tr>
<tr>
<td>Comorbidity, n (%)</td>
<td>427 (52)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>83 (11)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>179 (23)</td>
</tr>
<tr>
<td>Stroke</td>
<td>26 (3)</td>
</tr>
<tr>
<td>COPD</td>
<td>33 (4)</td>
</tr>
<tr>
<td>Migraine</td>
<td>15 (2)</td>
</tr>
<tr>
<td>History of cataract</td>
<td>227 (27)</td>
</tr>
<tr>
<td>Visited ophthalmologist, n (%)</td>
<td>286 (35)</td>
</tr>
<tr>
<td>Uses visual aid, n (%)</td>
<td>745 (95)</td>
</tr>
<tr>
<td>Visual aid works properly, n (%)</td>
<td>569 (72)</td>
</tr>
<tr>
<td>Using a walking aid outside, n (%)</td>
<td>309 (37)</td>
</tr>
<tr>
<td>Vision changes during the day, n (%)</td>
<td>310 (38)</td>
</tr>
<tr>
<td>Falls present (last 6 months)</td>
<td>266 (32)</td>
</tr>
</tbody>
</table>

Abbreviations: COPD = chronic obstructive pulmonary disease; IQR = interquartile range; NA = not applicable; NS = not significant; PD = Parkinson disease.

*\(p < 0.05\) was considered statistically significant.
**Effect on daily activities**

Figure 3 shows that patients with PD indicated more difficulties with daily activities due to ophthalmologic symptoms than controls ($\chi^2 [1, n = 1,097] = 86.22; p < 0.001$). Patients experienced the greatest interference of ophthalmologic symptoms when reading (52%), followed by driving a car (33%), watching television (28%), and working on the computer (28%). Participants with PD fell more frequently than controls (PD: 4% daily or weekly, 28% once or twice a month; controls: 0% daily or weekly, 12% once or twice a month; $p < 0.001$). The frequency of falls increased with a higher score on the VIPD-Q in both groups. A multivariate logistic regression showed that falling was related to higher VIPD-Q total scores (odds ratio, 1.043; 95% CI, 1.03–1.06; $p < 0.001$, $r = 0.049$) after correction for age, disease duration, LED, and sex. We found a weak, but significant, correlation between the VIPD-Q total score and disease duration (Pearson correlation $r = 0.18$, $p < 0.001$).

Furthermore, 53% (95% CI, 49–56) of patients with PD reported a moderate to severe effect of ophthalmologic symptoms on their quality of life, compared with 16% (95% CI, 12–21) of controls ($F_2 = 97.17$, $p < 0.001$).

---

**Figure 1** Boxplot of the median total score of the VIPD-Q in Parkinson’s Disease Questionnaire (VIPD-Q) score

Boxplot of the median total score of the VIPD-Q in Parkinson disease (PD) and the control group (n = 773, PD group; n = 224, control group). ***p < 0.05.

**Figure 2** Number of ophthalmologic symptoms reported per domain compared between patients with Parkinson disease (PD) and controls

Each pair of bars represents patients with PD and healthy controls. The bars are divided into the cumulative percentages of participants reporting no ophthalmologic symptoms, 1 ophthalmologic symptom, 2 ophthalmologic symptoms, 3 ophthalmologic symptoms, or 4 ophthalmologic symptoms. For example, in the domain of the ophthalmologic surface, only 37% of the patients with PD reported no symptoms, compared with 76% in the control group. In the control group in the domains intraocular, oculomotor, and optic nerve the option “4 symptoms” is 0%. In the control group in the domains oculomotor and optic nerve the option “3 symptoms” is 0%. ***p < 0.001.
Internal consistency
The internal consistency of the VIPD-Q was high with all 3 measurements for internal consistency: $\omega$ total 0.86 (95% CI, 0.84–0.87), greatest lower bound 0.86, Cronbach coefficient $\alpha$ 0.86 (95% CI, 0.84–0.87).

Discussion
In this study, we show that compared with controls, patients with PD have a higher prevalence of ophthalmologic symptoms, as reflected by a high VIPD-Q total score, suggesting that either PD itself or its treatment has an effect on ophthalmologic functions beyond the normal aging process. Moreover, ophthalmologic symptoms among patients with PD interfered with daily activities more frequently than in controls.

We showed that 82% of patients with PD reported at least 1 ophthalmologic symptom. This is higher than previously reported prevalence figures, which varied between 10% and 78%. Possible explanations for this discrepancy include the sample size (previous studies included only 10–100 participants) and the range of ophthalmologic symptoms that were studied. We included 848 patients and surveyed a very broad range of ophthalmologic symptoms and possible underlying ophthalmologic disorders. All investigated ophthalmologic symptoms were more common in patients with PD than controls. Alterations in the visual network from the retina to higher cortical brain regions have been found in PD, and may be the cause of ophthalmologic symptoms. As many as 63% of patients reported a problem in the ocular surface domain. In PD, the most common ocular surface disorder is dry eyes, which can cause decreased vision and contributes to reading difficulties. A significantly lower blink rate may lead to a less stable tear film by evaporation, causing dry eyes. This in turn may paradoxically lead to excessive blinking, watery eyes due to reflex tearing, and blepharospasm. Treatment of dry eyes with eyedrops is effective and has virtually no side effects. Treatments of other ocular surface disorders (e.g., blepharitis) are also noninvasive and may improve visual acuity. Although less frequent than among patients with PD, ocular surface complaints were also common among controls (24%), which is expected in an elderly population.

Ophthalmologic symptoms in the intraocular and optic nerve domain were twice as frequent among patients with PD than controls. These symptoms are caused most commonly by cataract formation. This higher prevalence of symptoms possibly caused by cataract in patients with PD could result from the disease process of PD itself, since prominent $\alpha$-synuclein accumulation is present in residual lens fragments of patients with PD. Other possible contributing factors include deposition of abnormally phosphorylated $\alpha$-synuclein in the inner retinal layers, leading to retinal dopamine depletion and retinal dysfunction, or damage to the ganglion cell axons, leading to optic nerve head atrophy. Also, there...
may be a relationship between PD and neovascular macular degeneration. All these factors could cause changes in color and contrast vision, metamorphopsia, or impaired night vision.\textsuperscript{31-33} In our population, 26\% of patients reported problems when reading a text on a colored or gray background, suggesting impaired contrast sensitivity, while 11\% did not see colors as brightly as before, suggesting decreased color vision. This supports the association of impaired contrast sensitivity and decreased color vision with the neurodegenerative process in PD.\textsuperscript{15,36} Oculomotor symptoms were also frequently reported by patients with PD. Diplopia is a well-established nonmotor symptom in PD.\textsuperscript{37} Oculomotor deficits in PD are thought to arise from deficits in oculomotor pathways in the brainstem, basal ganglia, and frontal lobes. Some may arise from dopamine depletion in the basal ganglia, causing excessive inhibition of the superior colliculus, which may lead to hypometric eye movements.\textsuperscript{38} In addition, cortical involvement in the disease process of PD may affect the cortical visual areas (including the frontal and parietal eye fields), which play an important role during the initiation of eye movements, anticipation of visual stimuli, target selection, and suppression of automatic responses to visual stimuli.\textsuperscript{39} As with many other ophthalmologic symptoms, patients with PD generally do not report diplopia spontaneously, hence treating physicians should actively ask for double vision and other ophthalmologic symptoms.\textsuperscript{39,40} In our study, 22\% of patients reported visual hallucinations, compared with 30\%–60\% in previous studies.\textsuperscript{41} This discrepancy may be caused by underreporting of visual illusions—having the feeling that someone is in the room or interpreting a shadow as a person—which were part of earlier studies, but not explicitly surveyed by the VIPD-Q. Visual hallucinations may result from the disease process itself, as well as from its treatment.\textsuperscript{21,42} Risk factors for visual hallucinations include ophthalmologic disorders, underlining the importance of recognizing ophthalmologic symptoms and starting early treatment when possible.\textsuperscript{21,43,44}

We found a significant negative effect of ophthalmologic symptoms on daily activities and quality of life in patients with PD. The effect of ophthalmologic symptoms may be particularly vexing for patients with PD because of their need to compensate for their motor deficits by guiding their movements visually. This is reflected by the 22\% of patients in this study who reported that ophthalmologic symptoms caused difficulties walking and performing hobbies. Also, patients with higher VIPD-Q scores reported more frequent falls. Visual deficits have frequently been associated with the postural instability and gait disorder phenotype, suggesting an association between the severity of ophthalmologic abnormalities and the severity of gait impairment.\textsuperscript{7,45,46} Furthermore, half of the patients experienced problems with reading. Reading difficulties may be caused by various ophthalmologic disorders (e.g., convergence insufficiency) as well as by concentration deficits. In this study, ophthalmologic symptoms interfered with driving a car among 33\% of patients. Difficulties driving a car have been attributed to impaired contrast sensitivity and visual processing in PD.\textsuperscript{47,48}

This is supported by our results, where 26\% of patients experienced problems with contrast vision, 43\% had difficulties driving at night, and 17\% had problems with depth perception. Ophthalmologic symptoms fluctuated during the day in around one-third of patients and may have varied depending on the specific activities at hand; for instance, diplopia may arise only during reading caused by convergence insufficiency, or blurry vision may occur preferentially in a crowded place in patients with impaired visual processing.\textsuperscript{39,49,50}

The observational nature of our study brings about some limitations. First, the sampling method may have led to a selection bias (patients with visual complaints being more likely to respond), potentially causing an overestimation of ophthalmologic symptoms. This selection bias may explain the higher total VIPD-Q score in patients with PD who participated through the open Web link compared with respondents by mail or interview. However, the patients selected in Innsbruck (where the risk of selection bias was low because of the inclusion procedure and high response rate) had an only slightly lower prevalence than what we found in the other sampling methods.

Furthermore, there is a potential self-report bias. This includes a self-report bias for the diagnosis of PD. Even in the hands of a neurologist, misclassification can be as high as 25\% of cases, and the percentage might have been even higher here. We tried to minimize this by inviting patients registered with a diagnosis of PD that was established by a neurologist with dedicated experience in movement disorders in all 3 centers.

Another limitation is the unvalidated nature of our questionnaire. The correlation between the ophthalmologic symptoms reported in the VIPD-Q and actual ophthalmologic diseases has not yet been established and this will be the objective of future research.\textsuperscript{13} Nevertheless, the high prevalence of ophthalmologic symptoms and their effect on daily life is striking, and emphasizes the need to address this subject in both research and clinical practice. Patients who report ophthalmologic symptoms need a referral for further evaluation. For those patients who do not volunteer problems themselves, a screening questionnaire such as the VIPD-Q may help with identifying ophthalmologic symptoms in PD that might otherwise be missed, thereby enabling timely referral and treatment. Further work is needed to optimize the present VIPD-Q for such use in screening.

**Acknowledgment**

The authors thank the patients and their families for participation.

**Study funding**

This study is funded by a research grant from the Stichting Parkinson Fonds (grant 38000). The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to
submit the manuscript for publication. No compensation from a funding source was received.

**Disclosure**

C.D.J.M. Borm, F. Visser, M. Werkmann, D. De Graaf, D. Putz, K. Seppi, W. Poewe, A. Vlaar, and C. Hoyng report no disclosures relevant to the manuscript. B.R. Bloem reports grants from the Michael J. Fox Foundation, ZonMw, Stichting Parkinson Nederland, Parkinson Vereniging, Hersenstichting Nederland, Parkinson’s Foundation, Verily Life Sciences, Horizon 2020, and Topsector Life Sciences and Health; grants and personal fees from UCB; and personal fees from AbbVie, Bial, and Zambon. T. Theelen and N.M. de Vries report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

**Publication history**

Received by *Neurology* July 18, 2019. Accepted in final form October 15, 2019.

**Appendix**

**Authors**

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Role</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlijn D.J.M. Borm, MD</td>
<td>Radboud University Medical Centre, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Designed and conceptualized study, major role in the acquisition of data, analyzed the data, drafted the manuscript for intellectual content</td>
</tr>
<tr>
<td>Femke Visser, MD</td>
<td>OLVG, Amsterdam, the Netherlands</td>
<td>Author</td>
<td>Designed and conceptualized study, major role in the acquisition of data, analyzed the data, drafted the manuscript for intellectual content</td>
</tr>
<tr>
<td>Mario Werkmann, MD</td>
<td>Medical University Innsbruck, Austria</td>
<td>Author</td>
<td>Designed and conceptualized study, major role in the acquisition of data</td>
</tr>
<tr>
<td>Debbie de Graaf, MSc</td>
<td>Radboud University Medical Centre, Nijmegen, the Netherlands</td>
<td>Major role in the acquisition of data</td>
<td></td>
</tr>
<tr>
<td>Diana Putz, MD</td>
<td>Medical University Innsbruck, Austria</td>
<td>Author</td>
<td>Interpreted the data, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Klaus Seppi, MD</td>
<td>Medical University Innsbruck, Austria</td>
<td>Author</td>
<td>Interpreted the data, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Werner Poewe, MD</td>
<td>Medical University Innsbruck, Austria</td>
<td>Author</td>
<td>Interpreted the data, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Annemarie M.M. Vlaar, MD, PhD</td>
<td>OLVG, Amsterdam, the Netherlands</td>
<td>Author</td>
<td>Interpreted the data, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Carel Hoyng, MD, PhD</td>
<td>Radboud University Medical Centre, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Interpreted the data, revised the manuscript for intellectual content</td>
</tr>
</tbody>
</table>

**References**

Seeing ophthalmologic problems in Parkinson disease: Results of a visual impairment questionnaire
Carlijn D.J.M. Borm, Femke Visser, Mario Werkmann, et al.
*Neurology* published online March 11, 2020
DOI 10.1212/WNL.0000000000009214

This information is current as of March 11, 2020

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://n.neurology.org/content/early/2020/03/11/WNL.000000000009214.full">http://n.neurology.org/content/early/2020/03/11/WNL.000000000009214.full</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s): All Neuro-ophthalmology <a href="http://n.neurology.org/cgi/collection/all_neuroophthalmology">http://n.neurology.org/cgi/collection/all_neuroophthalmology</a> Parkinson's disease/Parkinsonism <a href="http://n.neurology.org/cgi/collection/parkinsons_disease_parkinsonism">http://n.neurology.org/cgi/collection/parkinsons_disease_parkinsonism</a> Prevalence studies <a href="http://n.neurology.org/cgi/collection/prevalence_studies">http://n.neurology.org/cgi/collection/prevalence_studies</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a></td>
</tr>
</tbody>
</table>